{
    "organizations": [],
    "uuid": "1cd7c603808968c5e2c88abab6260bbf834b9a00",
    "author": "",
    "url": "https://www.reuters.com/article/brief-immunomedics-royalty-pharma-announ/brief-immunomedics-royalty-pharma-announce-royalty-funding-and-stock-purchase-agreements-totalling-250-mln-idUSFWN1P30LU",
    "ord_in_thread": 0,
    "title": "BRIEF-Immunomedics, Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totalling $250 Mln",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 8, 2018 / 1:40 PM / Updated 11 minutes ago BRIEF-Immunomedics, Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totalling $250 Mln Reuters Staff \nJan 8 (Reuters) - Immunomedics Inc: \n* IMMUNOMEDICS AND ROYALTY PHARMA ANNOUNCE ROYALTY FUNDING AND STOCK PURCHASE AGREEMENTS TOTALLING $250 MILLION \n* IMMUNOMEDICS INC - ROYALTY PHARMA ACQUIRES ROYALTY RIGHTS ON GLOBAL NET SALES OF SACITUZUMAB GOVITECAN (IMMU-132) ACROSS ALL INDICATIONS FOR $175 MILLION \n* IMMUNOMEDICS INC - ROYALTY PHARMA HAS ALSO PURCHASED $75 MILLION IN COMMON STOCK OF IMMUNOMEDICS, AT $17.15 PER SHARE \n* IMMUNOMEDICS - TRANSACTION WILL PROVIDE SUFFICIENT CASH TO FUND OPERATIONS INTO 2020 Source text for Eikon: Further company coverage:",
    "published": "2018-01-08T15:40:00.000+02:00",
    "crawled": "2018-01-08T15:58:34.007+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "royalty",
        "pharma",
        "announce",
        "royalty",
        "funding",
        "stock",
        "purchase",
        "agreement",
        "totalling",
        "mln",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "immunomedics",
        "inc",
        "immunomedics",
        "royalty",
        "pharma",
        "announce",
        "royalty",
        "funding",
        "stock",
        "purchase",
        "agreement",
        "totalling",
        "million",
        "immunomedics",
        "inc",
        "royalty",
        "pharma",
        "acquires",
        "royalty",
        "right",
        "global",
        "net",
        "sale",
        "sacituzumab",
        "govitecan",
        "across",
        "indication",
        "million",
        "immunomedics",
        "inc",
        "royalty",
        "pharma",
        "also",
        "purchased",
        "million",
        "common",
        "stock",
        "immunomedics",
        "per",
        "share",
        "immunomedics",
        "transaction",
        "provide",
        "sufficient",
        "cash",
        "fund",
        "operation",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}